Compare GSK plc (GSK) vs ON Holding AG (ONON) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

ONON trades at $38.26, up 1.38% today, with a neutral technical signal and strong fundamental momentum. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.43. Revenue reached $3.01B in 2025 with a net income margin of 8.02%, while cash flow from operations was $359.5M. Analyst sentiment is overwhelmingly positive, with 20 buy ratings and a consensus price target of $47.33.

Outlook remains favorable given consistent earnings beats and margin expansion, though elevated valuation ratios (P/E 40.42) pose a risk if growth slows. Key catalysts include Q2 2026 results and Asia-Pacific expansion, while competition and macroeconomic pressures represent headwinds for the premium athleticwear brand.